The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).
Ellen M. Lavoie Smith
No relevant relationships to disclose
Herbert Pang
No relevant relationships to disclose
Constance Cirrincione
No relevant relationships to disclose
Stewart Barry Fleishman
No relevant relationships to disclose
Electra D. Paskett
Research Funding - Merck
Camilo E. Fadul
No relevant relationships to disclose
Chetaye Knox
No relevant relationships to disclose
Charles L. Shapiro
No relevant relationships to disclose
Paul Gilman
No relevant relationships to disclose